SureNano Science Initiates FDA Stage GLP Toxicology and Pharmacology Studies for GLP GEP-44 and Enters Discussions to Acquire Ibogaine Formulation IP Portfolio
Vancouver, British Columbia – April 24, 2026 – SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (“SureNano” or the “Company”), parent company of GlucaPharm Inc. (“GlucaPharm”),...